UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Duration of the Anti-Androgen in Men Undergoing 6 Months of an LHRH Agonist and Radiation Therapy for Unfavorable-Risk Prostate Cancer and the Risk of Death

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E226-E227

2016

Link zum Volltext

Verfügbarkeit prüfen

Imaging yield from 133 consecutive patients with prostate cancer and low trigger PSA from a single institution

Clinical radiology, 2016-03, Vol.71 (3), p.e143-e149

2016

Link zum Volltext

Verfügbarkeit prüfen

Defining the Optimal Approach to the Patient With Postradiation Prostate-Specific Antigen Recurrence Using Outcome Data From a Prospective Randomized Trial

International journal of radiation oncology, biology, physics, 2013-10, Vol.87 (2), p.S156-S156

2013

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy for Advanced Prostate Cancer

Annals of oncology, 2012-09, Vol.23, p.ix38

Kantoff, P.W.

2012

Link zum Volltext

Verfügbarkeit prüfen

46IN - Immunotherapy for Advanced Prostate Cancer

Annals of oncology, 2012-09, Vol.23, p.ix38-ix38

Kantoff, P.W.

2012

Link zum Volltext

Verfügbarkeit prüfen

Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S88-S88

2014

Link zum Volltext

Verfügbarkeit prüfen

7002 ORAL Time to Disease-related Pain After Sipuleucel-T in Asymptomatic Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): Results From 3 Randomized Phase III Trials

European journal of cancer (1990), 2011, Vol.47, p.S484-S484

2011

Link zum Volltext

Verfügbarkeit prüfen

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

The New England journal of medicine, 2016-08, Vol.375 (5), p.443-453

2016

Link zum Volltext

Verfügbarkeit prüfen

The Impact of Genetic Variants in the Double-Stranded DNA Break Repair Pathway on Cancer Control in Men Treated with Radiation for Prostate Cancer

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S380-S380

2011

Link zum Volltext

Verfügbarkeit prüfen

Post-Treatment Prostate-Specific Antigen Nadir is Predictive of All-Cause Mortality: A Reanalysis of the Dana Farber Cancer Institute Radiation With or Without Androgen Deprivation Therapy Randomized Trial

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S417-S418

2011

Link zum Volltext

Verfügbarkeit prüfen

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Annals of oncology, 2016-03, Vol.27 (3), p.454-460

2016

Link zum Volltext

Verfügbarkeit prüfen

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

Oncogene, 2007-07, Vol.26 (31), p.4596-4599

2007

Link zum Volltext

Verfügbarkeit prüfen

Comorbidity, Body Mass Index, and Age and the Risk of Non-prostate Cancer-specific Mortality following a Postradiation PSA Recurrence

International journal of radiation oncology, biology, physics, 2009, Vol.75 (3), p.S495-S495

2009

Link zum Volltext

Verfügbarkeit prüfen

1773P ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era

Annals of oncology, 2023-10, Vol.34, p.S958-S959

2023

Link zum Volltext

Verfügbarkeit prüfen

Role of diet in prostate cancer: the epigenetic link

Oncogene, 2015-09, Vol.34 (36), p.4683-4691

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of sunitinib in men with advanced prostate cancer

Annals of oncology, 2009-05, Vol.20 (5), p.913-920

2009

Link zum Volltext

Verfügbarkeit prüfen

681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc)

Annals of oncology, 2020-09, Vol.31, p.S542-S542

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)

Annals of oncology, 2018-10, Vol.29, p.viii298-viii298

2018

Link zum Volltext

Verfügbarkeit prüfen

Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer

Prostate cancer and prostatic diseases, 2014-12, Vol.17 (4), p.325-331

2014

Link zum Volltext

Verfügbarkeit prüfen

P075 - SHORT-TERM OUTCOMES FOLLOWING ORAL HORMONAL PROSTATE CANCER THERAPIES BY PRE-EXISTING CARDIOVASCULAR CONDITIONS: A POPULATION-BASED STUDY

Journal of geriatric oncology, 2019-11, Vol.10 (6), p.S72-S72

2019

Link zum Volltext

Verfügbarkeit prüfen

SHORT-TERM OUTCOMES FOLLOWING ORAL HORMONAL PROSTATE CANCER THERAPIES BY PRE-EXISTING CARDIOVASCULAR CONDITIONS: A POPULATION-BASED STUDY

Journal of geriatric oncology, 2019-11, Vol.10 (6), p.S72

2019

Link zum Volltext

Verfügbarkeit prüfen

7002 Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC)

European journal of cancer supplements, 2009, Vol.7 (2), p.406-406

2009

Link zum Volltext

Verfügbarkeit prüfen

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

Prostate cancer and prostatic diseases, 2014-09, Vol.17 (3), p.259-264

2014

Link zum Volltext

Verfügbarkeit prüfen

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

Annals of oncology, 2012-05, Vol.23 (5), p.1234-1240

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

Humans
(13)
Male
(12)
Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Aged
(9)
Middle Aged
(9)
Oncology
(9)
Hematology, Oncology And Palliative Medicine
(8)
Prostate Cancer
(7)
Radiology
(7)
Aged, 80 And Over
(6)
Biological And Medical Sciences
(5)
Prostatic Neoplasms - Pathology
(5)
Tumors
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Medical Sciences
(4)
Original
(4)
Prostate-Specific Antigen - Blood
(4)
Prostatic Neoplasms - Drug Therapy
(4)
Adult
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Duration of the Anti-Androgen in Men Undergoing 6 Months of an LHRH Agonist and Radiation Therapy for Unfavorable-Risk Prostate Cancer and the Risk of Death

Imaging yield from 133 consecutive patients with prostate cancer and low trigger PSA from a single institution

Defining the Optimal Approach to the Patient With Postradiation Prostate-Specific Antigen Recurrence Using Outcome Data From a Prospective Randomized Trial

Immunotherapy for Advanced Prostate Cancer

46IN - Immunotherapy for Advanced Prostate Cancer

Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer

7002 ORAL Time to Disease-related Pain After Sipuleucel-T in Asymptomatic Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): Results From 3 Randomized Phase III Trials

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

The Impact of Genetic Variants in the Double-Stranded DNA Break Repair Pathway on Cancer Control in Men Treated with Radiation for Prostate Cancer

Post-Treatment Prostate-Specific Antigen Nadir is Predictive of All-Cause Mortality: A Reanalysis of the Dana Farber Cancer Institute Radiation With or Without Androgen Deprivation Therapy Randomized Trial

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

Comorbidity, Body Mass Index, and Age and the Risk of Non-prostate Cancer-specific Mortality following a Postradiation PSA Recurrence

1770O Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): An individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium

1773P ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era

Role of diet in prostate cancer: the epigenetic link

Phase II study of sunitinib in men with advanced prostate cancer

681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc)

Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)

Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer

P075 - SHORT-TERM OUTCOMES FOLLOWING ORAL HORMONAL PROSTATE CANCER THERAPIES BY PRE-EXISTING CARDIOVASCULAR CONDITIONS: A POPULATION-BASED STUDY

SHORT-TERM OUTCOMES FOLLOWING ORAL HORMONAL PROSTATE CANCER THERAPIES BY PRE-EXISTING CARDIOVASCULAR CONDITIONS: A POPULATION-BASED STUDY

7002 Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC)

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

Suchergebnisse filtern